Redenlab Inc.

@redenlab.bsky.social

36 Followers 16 Following

A neuroscience-driven techbio. We use speech and language biomarkers to make clinical trials smarter. Shaping the future of speech in health. 🌐 https://redenlab.com/ 🔗 https://linkedin.com/company/redenlab/

Publication highlights: What can speech tell us about pain?

PUBLICATION HIGHLIGHTS: Speech and language biomarkers for Parkinson’s disease prediction, early diagnosis and progression

See you at Alzheimer's Association International Conference at 13-14 July, London.

With Prof Adam Vogel, CEO of Redenlab.

See you at International Conference on Primary Progressive Aphasia. Happening 16 - 17 July at University College of London.

Redenlab's CEO Professor Adam Vogel will be presenting "Not all ASR is equal: a multimetric comparison of automatic speech recognition systems for dementia speech".

21st June is Global MND Awareness Day. MND robs people of their voice. We're working to track every change.

1 in 300 people will develop MND in their lifetime. No cure and few effective treatments exist today.

Lottie Gasparini, Clinical Linguist & Researcher of Redenlab, said: "Language is key for communicating with others and participating in everyday life."

See you at 9th Annual Digital Biomarkers in Clinical Trials Summit on 23 June at Basel.

With Redenlab's CEO - Prof Adam Vogel, Chief Medical Officer - Dr Gustavo Noffs, and Director of Clinical Projects - Lisa Graf.

See you at National Aged Care Convention 2026.

Prof Adam Vogel (CEO of Redenlab) will be presenting "Early speech changes as clinical clues for cognitive decline" on 21 May 2026, 1:50PM at Royal Randwick Racecourse, Sydney.

Photo of Rupali, Redenlab's Quality Assurance Manager, on the right. A quote from her on the left hand side: "I take pride in strengthening Redenlab’s foundation in quality, compliance, and continuous improvement."

Publication highlights of the paper "Speech and language classification in the human phenotype ontology (HPO)". The right hand side features a photo of children undergoing speech therapy.

Cover page with title: Publication Highlights
"Examination of speech processing in noise reveals cognitive deficits in early Huntington's disease (HD)"

Publication highlights: Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia: treating mitochondrial dysfunction with anaplerosis.

New publication by Redenlab: rapid repetitive syllable sounds associate with episodic memory, executive function, and working memory in cognitively healthy and subjectively impaired older adults.